Cipla Q1 Result: Net profit grows 10% YoY; US business revenue stands at $226 million

The company’s total revenue from operations stood at ₹6,957 crore year-on-year (YoY) for the quarter under review as compared to ₹6,694 crore, marking an increase of 4%.

Cipla’s operating profit, or earnings before interest, taxes, depreciation, and amortisation (EBITDA), witnessed a growth of 3.6% at ₹1,778 crore as against ₹1,716 crore YoY.

In Q1, the firm’s margin remained flat at 25.6% YoY.

Cipla’s One India Business delivered a growth of 6% YoY for the quarter, breaching the threshold of ₹3,000 crore for the first time ever in the opening quarter of any financial year, it said.

Following the earnings, shares of Cipla were trading at ₹1,532 apiece, rising 2.96% on NSE.

The drugmaker’s US business delivered a quarterly revenue of $226 million, supported by traction in differentiated assets.

Revenue and development (R&D) investments of the drugmaker stood at ₹432 crore, or 6.2% of sales, driven by product filings and development efforts.

Cipla’s growth momentum for Africa business continued with overall revenue growth at 11% YoY in dollar terms. Its emerging markets and Europe also posted a healthy revenue growth of 8% YoY in USD terms.

“I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY26, we delivered steady revenue of INR 6,957 Cr, with a healthy EBITDA margin of 25.6%. What makes this performance commendable is that it builds on a strong prior-year quarter, where we achieved our highest-ever US Generics revenue,” said Umang Vohra, MD and Global CEO, Cipla.

“Going ahead, the focus will be on growing our key markets, further building our flagship brands, and investing in future pipelines, as well as focusing on resolutions on the regulatory front,” Vohra further added.

Cipla said that in India key therapies like respiratory, urology, cardiac, anti-diabetes, and anti-infectives grew faster than the market, with the overall chronic mix at 61.5% as per IQVIA MAT June 2025. During the quarter, the pharma company has successfully launched Voltido Trio, a flagship addition to the respiratory portfolio.

The India business recorded strong growth, and the performance was supported by execution excellence in key therapies, new introductions, and technological interventions. “The business launched 7 new products in Q1 FY26, including entry into orthopaedics to expand therapy coverage,” Cipla said in a statement.